Guidelines to Agencies on Governmentwide Debarment and Suspension (2 CFR 376 et seq.); and
(2) Dr. Bhrigu is prohibited from serving in any advisory capacity to the U.S. Public Health Service (PHS),
including but not limited to service on any PHS advisory committee, board,
and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative Oversight,
Office of Research Integrity.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. 2011–10157 Filed 4–26–11; 8:45 am]
BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI)
has taken final action in the following case:
Junghee J. Shin, PhD, New York Medical College: Based on the report of
an investigation conducted by New York Medical College (NYMC) and
additional analysis by the Office of Research Integrity (ORI) in its oversight
review, the U.S. Public Health Service (PHS) found that Junghee J. Shin, PhD,
former graduate student, NYMC,
engaged in research misconduct in research supported by National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health
(NIH), grants R01 AI048856 and R01 AI043063.
PHS found that the Respondent
engaged in research misconduct by falsifying data in Figure 4 of a
manuscript submitted to the journal
Infection and Immunity (Shin, J.J.,
Godfrey, H.P., & Cabello, F.C.
“Expression and localization of BmpC in
Borrelia burgdorferi after growth under various environmental conditions.”
Submitted to Infection and Immunity; hereafter referred to as the
“manuscript”) and Figure 5 of a paper
published in Infection and Immunity
(Shin, J.J., Bryksin, A.V., Godfrey, H.P.,
& Cabello, F.C. “Localization of BmpA
on the exposed outer membrane of
Borrelia burgdorferi by monospecific
anti-recombinant BmpA rabbit
antibodies.” Infection and Immunity
72(4):2280–2287, April 2004: hereafter referred to as the “paper.” Retracted in:
Infection and Immunity 76(10):4792,
October 2008). Specifically, NYMC and
ORI found that:
• Dr. Shin falsified microscopic
immunofluorescence blank images in
Figure 4 of the manuscript (top row, 1st,
2nd, 4th, and 5th panels, and bottom row,
1st panel) and Figure 5 of the paper
(top row, 1st and 5th panels, lower 1st
panel) by using one blank image from an
unknown experiment to falsely
represent the preimmunization control
conditions (intact cells and methanol
fixation) as well as the negative staining
of anti-BmpC and anti-FlaB in Figure 4
and anti-FlaB in Figure 5 on intact cells.
• Dr. Shin falsified at least one of two
images in Figure 4 of the manuscript
and Figure 5 of the paper by using
different portions of a green-red pair of
microscopic immunofluorescence
images (1230036.tif and 1230037.tif)
because unfixed cells staining positive
for BmpA in the top row, 4th panel of
Figure 5 were the same unfixed cells
purportedly positive for OspA in the top
row, 3rd panel, of Figure 4.
• Dr. Shin falsified at least one of two
images in Figure 4 of the manuscript
and Figure 5 of the paper by using
different photo cropping from a single
microscopic immunofluorescence
image (1230039.tif) to represent fixed cells
positive for BmpA and labeled with
anti-FlaB in the lower row, 5th panel, of
Figure 5 and to also represent fixed cells
positive for BmpC and stained with
anti-FlaB in the lower row, 5th panel, of
Figure 4.
Dr. Shin has entered into a Voluntary
Settlement Agreement in which she has
voluntarily agreed, for a period of three
(3) years, beginning on April 5, 2011:
(1) That any institution that submits
an application for PHS support for a
research project on which the
Respondent’s participation is proposed
or that uses her in any capacity on PHS-
supported research, or that submits a
report of PHS-funded research in
which she is involved, must concurrently
submit a plan for supervision of her
duties to ORI for approval; the
supervisory plan must be designed to
ensure the scientific integrity of her
research contribution; Respondent
agrees that she will not participate in
any PHS-supported research until such
a supervision plan is submitted to ORI;
and
(2) to exclude herself voluntarily from
service in any advisory capacity to PHS,
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative Oversight,
Office of Research Integrity.
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. 2011–10157 Filed 4–26–11; 8:45 am]
BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
[CDC–2011–0005]
Availability of Draft Toxicological Profile
AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR),
Department of Health and Human Services (DHHS).
ACTION: Notice of availability.
SUMMARY: This notice announces the
availability of the Toxicological Profile for
Uranium (Update) for review and comment.
These comments can include additional
information or reports on
studies about the health effects of
uranium. Although ATSDR considered
key studies for uranium during the
profile development process, this
Federal Register notice solicits any
relevant, additional studies, particularly
unpublished data. ATSDR will evaluate
the quality and relevance of such data
or studies for possible addition to the
profile. ATSDR remains committed to
providing a public comment period for
this document as a means to best serve
public health and our clients.
The Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA), as amended by
the Superfund Amendments and
Reauthorization Act of 1986 (SARA),
§ 104(i)(3), [42 U.S.C. 9604(i)(3)], directs
the ATSDR administrator to prepare
toxicological profiles of priority
hazardous substances and, as necessary,
to revise and publish each updated
toxicological profile.
DATES: To be considered, comments on
this draft toxicological profile must be
received not later than July 29th, 2011.
Comments received after the close of the
public comment period will be
considered at the discretion of ATSDR,
based upon what is deemed to be in the
best interest of the general public.
ADDRESSES: Requests for printed copies
of the draft toxicological profile should be
sent via e-mail to cdcinfo@cdc.gov, or
to Ms. Delores Grant, Division of Toxicology and Environmental Medicine, Agency for Toxic Substances and Disease Registry, Mailstop F–62, 1600 Clifton Road, NE., Atlanta, Georgia 30333. Electronic access to this document is also available at the ATSDR Web site: http://www.atsdr.cdc.gov/toxprofiles/index.asp.

Electronic comments may be sent via http://www.regulations.gov, docket number CDC–2011–0005. Please follow the directions on the site to submit comments. Comments may also be sent to the attention of Ms. Nickolette Roney, Division of Toxicology and Environmental Medicine, Agency for Toxic Substances and Disease Registry, Mailstop F–62, 1600 Clifton Road, NE., Atlanta, Georgia 30333. e-mail: tppubliccomment@cdc.gov. Send one copy of all comments and three copies of all supporting documents. Because all public comments regarding ATSDR toxicological profiles are available for public inspection, no confidential business information or other confidential information should be submitted in response to this notice.

FOR FURTHER INFORMATION CONTACT: Ms. Delores Grant, Division of Toxicology and Environmental Medicine, Agency for Toxic Substances and Disease Registry, Mailstop F–62, 1600 Clifton Road, NE., Atlanta, Georgia 30333, telephone (770) 488–3351.

SUPPLEMENTARY INFORMATION:

The Superfund Amendments and Reauthorization Act (SARA) (Pub. L. 99–499) amends the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or Superfund) (42 U.S.C. 9601 et seq.) by establishing certain responsibilities for ATSDR and the U.S. Environmental Protection Agency (U.S. EPA) with regard to hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL). As part of these responsibilities, the ATSDR administrator must prepare toxicological profiles for substances enumerated on the priority list of hazardous substances. This list identifies 275 hazardous substances which, according to ATSDR and U.S. EPA, pose the most significant potential threat to human health. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on March 6, 2008 (73 FR 12178). In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to “... * * establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(j)(1)(B), to respond to requests for consultation under section 104(j)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

Each profile will include an examination, a summary, and an interpretation of available toxicological information and epidemiological evaluations. This information and these data identify the levels of significant human exposure for the substance and for the associated health effects. The profiles must also include a determination of whether adequate information on the health effects of each substance is available or is in the process of development. If adequate information is not available, ATSDR, in cooperation with the National Toxicology Program (NTP), is required to ensure the initiation of research to determine such health effects.

All toxicological profiles issued as “Drafts for Public Comment” represent ATSDR’s best efforts to provide important toxicological information on priority hazardous substances. The draft toxicological profile will be made available to the public on or about April 29th, 2011.

<table>
<thead>
<tr>
<th>Hazardous substance</th>
<th>CAS No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uranium (Update)</td>
<td>7440–61–1</td>
</tr>
</tbody>
</table>

Dated: April 21, 2011.

Ken Rose,
Director, Office of Policy, Planning and Evaluation, National Center for Environmental Health/Agency for Toxic Substances and Disease Registry.

[FR Doc. 2011–10146 Filed 4–26–11; 8:45 am]
BILLING CODE 4153–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day–11–11EQ]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 404–639–5960 and send comments to Daniel Holcomb, CDC Reports Clearance Officer, 1600 Clifton Road, MS–D74, Atlanta, GA 30333 or send an e-mail to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice.

Proposed Project

Environmental Health Specialists Network (EHS-Net) National Voluntary Environmental Assessment Information System (NVEAIS)—New—National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The CDC is requesting OMB approval for the EHS-Net National Voluntary Environmental Assessment Information System (NVEAIS) to collect data from foodborne illness outbreak environmental assessments routinely conducted by local, state, territorial, or tribal food safety programs during outbreak investigations. Environmental assessment data are not currently collected at the national level. The data reported through this information system will provide timely data on the causes of outbreaks, including environmental factors associated with outbreaks, and are essential to environmental public health regulators’ efforts to respond more effectively to outbreaks and prevent future, similar outbreaks. This information system is specifically designed to link to CDC’s existing disease outbreak surveillance system (National Outbreak Reporting System).

The information system was developed by the Environmental Health Specialists Network (EHS-Net), a collaborative project of CDC, the U.S. Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA), and nine states (California, Connecticut, Georgia, Iowa, New York, Minnesota, Oregon, Rhode Island, and